MAM14 Immunotherapy Protocol: The Dream of Ophthalmologist, Became at Your Door. This Protocol Can Treat Autoimmune Uveitis.
Uveitis doesn't have to involve a lifelong treatment course (C Stephen Foster). In this article we replaced conventional steroid and other immunosuppressant treatment by safe and new immunomodulation called MAM14 immunotherapy protocol, designed to treat uveitis. Our objective is to replace steroid and other immunosuppresant with safe effective immunomodulation method. As a first trial to study this protocol, we choose one hundred twelve female uveitis patients called: experimental group; their age range between 13-15 years old, treated by MAM14 immunotherapy, which is briefly, paternal stressed allogeneic lymphocyte vaccination given subcutaneously to their daughters. Compared to 120 female control group uveitis patients age range between 12-16 years old received routine prednisone eye drops (Pred Forte). Results for the Slit lamp microscope showed that the experimental group demonstrates remarkable improvement duration of treatment four to nine months. Improvement lasted for ten years. No side effect noted during experiment and until this writing compared to control. Pachymeter showed no degradation of cornea and slit lamp showed no lymphocyte infiltration